Trading volumes must have been very low this week as everyone was bust eating mince pies. There was only one share that moved by more than 5% and it was OPTI:Optibiotix, climbing 7p which was 10% and storming to Share of the Week for the second week in a row.
Back up to where is was a few months ago. Hopefully this time it will keep going.
That should start to heave the trend line flat
Here's the ISA and share accounts performance
| Weekly Change | |||
| Cash | £15.74 | +£0 | |
| Portfolio cost | £57,768.95 | +£0 | |
| Portfolio sell value (bid price-commission) | £45,363.65 | (-21.5%) | +£4,099.70 |
| Potential profits | £0 | +£0 | |
| Yr 5 Dividends | £0.63 | +£0 | |
| Yr 5 Profit from sales | £-167.28 | +£0 | |
| Yr 5 Average monthly cash profit | -£37.48 | (-0.8%) | +£1.88 |
| Total Dividends | £1,342.93 | +£0 | |
| Total Profit from sales | £20,224.13 | +£0 | |
| Average monthly cash profit | £404.20 | (8.4%) | -£1.77 |
| (Sold stocks profit + Dividends - Fees / Months) | |||
| Performance/Injection | 13.0% | -0.1% | |
| Compound performance | 57% | +0% |
With so few movers the increased value was all down to OPTI:Optibiotix. This was helped by someone spotting an Instagram post showing a picture of Holland & Barrett's Slimbiome - confirming the first UK retail opportunity and causing a ripple of optimism. Marketing should kick in next week, so let's see what happens.
This is still closer to the injection line than the cost line, so a long way to go yet.
This should really help flatten the trend line, if it lasts.
Here's the SIPP after week 213
| Weekly Change | ||||
| Cash | £90.96 | +£0 | ||
| Portfolio cost | £46,995.31 | +£0 | ||
| Portfolio sell value (bid price - commission) |
£41,309.02 | (-12.1%) | +£3,404.41 | |
| Potential profits | £647.97 | -£75.00 | ||
| Yr 5 Dividends | £0 | +£0 | ||
| Yr 5 Interest | £0 | +£0 | ||
| Yr 5 Profit from sales | £0 | +£0 | ||
| Yr 5 Average monthly cash profit | -£10.71 | (-0.3%) | +£2.68 | |
| Total Dividends | £1,899.24 | +£0 | ||
| Total Interest | £0.17 | +£0 | ||
| Total Profit from sales | £12,549.10 | +£0 | ||
| Average monthly cash profit | £284.67 | (7.3%) | -£1.35 | |
| (Sold stocks profit + Dividends - Fees / Months) | ||||
| Performance/Injection | 11.4% | -0.1% | ||
| Compound performance | 47% | +0% |
Similar story to the ISA, with OPTI:Optibiotix accounting for nearly all the rise. Slight downer as the drop in CAML:Central Asia Metals reduced paper profits by £75.
Not too far from getting back into the black.
We've been here before so I'll postpone any celebrations until we go back into the black.
The trading account looks like this after week 179
| Weekly Change | |||
| Cash | £48.24 | +£0 | |
| Portfolio cost | £2,321.29 | +£0 | |
| Portfolio sell value (bid price - commission) | £1,247.82 | (-46.2%) | +£13.35 |
| Potential profits | £0 | +£0 | |
| Year 4 Dividends | £13.20 | +£0 | |
| Year 4 Profit | £0 | +£0 | |
| Yr 4 Average monthly cash profit | £2.49 | (1.3%) | -£0.11 |
| Dividends | £47.92 | +£0 | |
| Profit from sales | -£64.29 | +£0 | |
| Average monthly cash profit | -£0.40 | (-0.2%) | +£0 |
| (Sold stocks profit + Dividends - Fees / Months) | |||
| Performance/Injection | -0.2% | +0% | |
| Compound performance | -1% | +0% |
Increases in IQE:IQE and TRMR:Tremor were enough to offset the drop in CAML:Cental Asia Metals and increase portfolio value by £13. Still miles away from being able to sell anything though. When I do get to sell something, I need to vow to start trading whatever I buy properly and not treat this as a normal investment account.
Still pretty desperate
Back on the trend line but not yet above it.
Here's my virtual magic formula account performance
| Weekly Change | |||
| Cash | £153.61 | +£0 | |
| Portfolio cost | £29,846.39 | +£0 | |
| Portfolio sell value (bid price - commission) | £31,100.73 | (+4.2%) | +£145.87 |
| Potential profits | £1,531.46 | +£450.59 | |
| Year 1 Dividends | £0 | +£0 | |
| Year 1 Profit | £0 | +£0 | |
| Yr 1 Average monthly cash profit | £0 | (0%) | +£0 |
| Dividends | £0 | +£0 | |
| Profit from sales | £0 | +£0 | |
| Average monthly cash profit | £0 | (0%) | +£0 |
| (Sold stocks profit + Dividends - Fees / Months) |
Another good week. I've not really had time to look into any of the companies in my top 30, but it will be at least 4 months until I have any cash to start up the real shares, so plenty of time to get to know them.
There has been one change in the top 30, with BDEV:Barratt Developments dropping out and NXT:Next appearing. It appears the massive post-election spike in BDEV share price has increased the P/E ratio enough for it to no longer class as cheap. There has been no drop in NXT share price though, which has an impressive growth record, but will their return on capital hold up in their next results?
I'll stick to the rules and hold these for a full 12 months before selling anything.
I suspect next week will be another light one for trading, so not anticipating much change. If Holland & Barrett start marketing Slimbiome then we could see another tick up for OPTI:Optibiotix. I only need a 2p rise to be back in the black for this share, and every penny above that is worth £1,050. I'd be happy just to have something other than just CAML:Central Asia Metals showing green on my spreadsheet.
No comments:
Post a Comment